Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Chronic Constipation

NCT00730015 is registered in ClinicalTrials.gov with Ironwood Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00730015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00730015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Chronic Constipation
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2008
Completion date
October 31, 2009
Enrollment
643 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

chronic constipation